Differential pharmacotherapy for subgroups of fibromyalgia patients with specific consideration of 5-HT3 receptor antagonists

Bibliography

• Wolfe F, Smythe HA, Junus MB, The American College of Rheumatology 1990 criteria for th classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
   PubMed Web of Science ®Google Scholar
• Wolfe F, Clauw DJ, Fitzcharles MA, The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010;62(5):600-10
   PubMed Web of Science ®Google Scholar
• Kohnen R, Farber L, Spath M. The assessment of vegetative and functional symptoms in fibromyalgia patients: the tropisetron experience. Scand J Rheumatol 2004;33(Suppl 119):67-71
   Google Scholar
• Koeppe C, Schneider C, Thieme K, The influence of 5HT3 receptor antagonist tropisetron on pain in fibromyalgia: a functional magnetic resonance imaging pilot study. Scand J Rheumatol 2004;33(Suppl 119):24-7
   PubMedGoogle Scholar
• Ray SR, Brouillard D, Simpson CS, Dysautonomia among patients with fibromyalgia: a non-invasive assessment. J Rheumatol 2000;27:2660-5
   PubMed Web of Science ®Google Scholar
• Lapossy E, Gasser P, Hrycaj P, Cold induced vasospasm in patients with fibromyalgia and chronic low back pain in comparison to healthy subjects. Clin Rheumatol 1994;13:442-5
   PubMed Web of Science ®Google Scholar
• Seidel M, Weinreich GF, Stratz T, Muller W. 5HT3 receptor antagonists regulate autonomic cardial dysfunction in primary fibromyalgia syndrome. Rheumatol Int 2007;27:1025-30
   PubMed Web of Science ®Google Scholar
• Gracely RH, Petzke F, Wolf JM, Crauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002;46:1333-43
   PubMed Web of Science ®Google Scholar
• Stratz T, Schochat T, Farber L, Are there subgroups in fibromyalgia? J Musculoskelet Pain 1995;3(Suppl 1):15
   Google Scholar
• Endresen GKM. Fibromyalgia: a rheumatological diagnosis. Rheumatol Int 2007;27(11):999-1004
   PubMed Web of Science ®Google Scholar
• Kelemen J, Stratz T, Muller W. Secondary fibromyalgia. Fortsch Med 1998;116:31-6
   Google Scholar
• Muller W, Schneider EM, Stratz T. The classification of fibromyalgia syndrome. Rheumatol Int 2007;27:1005-10
   PubMed Web of Science ®Google Scholar
• de Souza JB, Goffaux P, Julien N, Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Impact Questionnaire. A preliminary study. Rheumatol Int 2009;29(5):509-15
   PubMed Web of Science ®Google Scholar
• Calandre EP, Garcia-Carrillo J, Garcia-Leiva JM, . Subgrouping patients with fibromyalgia according to the results of the fibromyalgia impact questionnaire: a replication study. Rheumatol Int 2010. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Giesecke T, Williams DA, Harris RE, Subgrouping of fibromyalgia patients on the basis of pressure-pain threshold and psychological factors. Arthritis Rheum 2004;50:2716-17
   PubMedGoogle Scholar
• Thieme K, Turk DC, Flor H. Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom Med 2004;66:837-44
   PubMed Web of Science ®Google Scholar
• Hauser W, Bernardy K, Arnold B. Fibromyalgia – a somatoform (pain) disorder? Schmerz 2006;20:128-39
   PubMed Web of Science ®Google Scholar
• Oppenheim RW. Cell death during development of the nervous system. Ann Rev Neurosci 1991;14:453-501
   PubMed Web of Science ®Google Scholar
• Seidel MF, Herguijuela M, Forkert R, Otten U. Nerve growth factor in rheumatic diseases. Semin Arthritis Rheum 2010;40(2):109-26
   PubMed Web of Science ®Google Scholar
• Seidel M, Tsalik J, Vetter H, Muller W. Substance P in rheumatic diseases. Curr Rheum Rev 2007;3:17-30
   Google Scholar
• Lembeck F, Hozer P. Substance P as neurogenic mediator of antidromic vasodilatation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 1979;310:175-83
   PubMed Web of Science ®Google Scholar
• Roberts MH. Pharmacology of putative neurotransmitters and receptors: 5-hydroxytryptamine. Prog Brain Res 1988;77:329-38
   PubMed Web of Science ®Google Scholar
• Seidel MF, Fiebich BL, Ulrich-Merzenich G, Serotonin mediates PGE(2) overexpression through 5-HT(2A) and 5-HT(3) receptor subtypes in serum-free tissue culture of macrophage-like synovial cells. Rheumatol Int 2008;28(10):1017-22
   PubMed Web of Science ®Google Scholar
• Maleki-Dizaji N, Eteraf-Oskouei T, Fakhrjou A, The effects of 5HT3 receptor antagonist granisetron on inflammatory parameters and angiogenesis in the air-pouch model of inflammation. Int Immunopharmacol 2010;10(9):1010-16
   PubMed Web of Science ®Google Scholar
• Berberich F, Hoheisel U, Mense S, Scheppar P. Fine muscle afferent fibers and inflammation: changes in discharge behaviour and influence on gamma motoneurones. In: Schmidt RF, Schaible H-G, Vahle-Hinz C, editors, Fine afferent nerve fibers in pain. VCH-Verlag, Weinheim; 1987. p. 165-75
   Google Scholar
• Diehl H, Hoheisel U, Mense S. Histological and neurophysiological changes induced by carrageenan in skeletal muscle of cat and rat. Agents Actions 1988;25:210-13
   PubMedGoogle Scholar
• Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 2005;114:295-302
   PubMed Web of Science ®Google Scholar
• Mense S. Neurobiological concepts of fibromyalgia – the possible role of descending spinal tracts. Scand J Rheumatol 2000;29(Suppl 113):24-9
   Google Scholar
• Riering K, Rewerts C, Zieglgansberger W. Analgetic effects of 5HT3 receptor antagonists. Scand J Rheumatol 2004;33(Suppl 119):19-23
   PubMedGoogle Scholar
• Fiebich BL, Akundi RS, Lieb K, Antiinflammatory effects of 5-HT3 receptor antagonists in lipopolysaccharide-stimulated primary human monocytes. Scand J Rheumatol 2004;33(Suppl 119):28-32
   Google Scholar
• Giordano J, Daleo C, Sacks SM. Topical ondansetron attenuates nociceptive and antiinflammatory effects of intradermal capsaicin in humans. Eur J Pharmacol 1998;354:R13-14
   PubMed Web of Science ®Google Scholar
• Kukushkin ML, Igonkina SI. Role of 5HT3 receptors in the mechanism of central pain syndrome. Bull Exp Biol Med 2003;135:552-5
   PubMed Web of Science ®Google Scholar
• Zeitz KP, Guy N, Malberg AB, The 5HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J Neurosci 2002;22:1010-19
   PubMed Web of Science ®Google Scholar
• Mense S, Simons DG, Russel JJ. Muscle pain understanding its nature, diagnosis and treatment. Lippincott, Williams and Williams, Philadelphia; 2001
   Google Scholar
• Papadopoulos IA, Glorgiou PE, Katsimtri PP, Drossos AA. Treatment of fibromyalgia with tropisetron, a 5HT3 receptor antagonist: a pilot study. Clin Rheumatol 2000;19:6-8
   PubMed Web of Science ®Google Scholar
• Muller W, Stratz T, Schochat T, Mennet P. The therapy of fibromyalgia with 5HT3 receptor antagonists. Z Rheumatol 1994;53(Suppl 1):24
   Google Scholar
• Farber L, Stratz T, Bruckle W, Efficacy and tolerability of tropisetron in primary fibromyalgia – a highly selective and competitive 5HT3 receptor antagonist. Scand J Rheumatol 2000;29(Suppl 113):49-54
   Google Scholar
• Oliver B, Van Wijngaarden I, Soudij W. 5HT(3) receptor antagonists and anxiety; a preclinical and clinical review. Eur Neuropsychopharmacol 2000;10:77-95
   PubMed Web of Science ®Google Scholar
• Varga B, Farber L, Kohnen R, Four week therapy with the 5HT3 receptor antagonist tropisetron in fibromyalgia. Akt Rheumatol 2000;25:43-50
   Web of Science ®Google Scholar
• Haus U, Varga B, Stratz T, Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol 2000;29(Suppl 113):55-8
   Google Scholar
• Stratz T, Varga B, Muller W. The influence of depression on the therapy of fibromyalgia. Z Rheumatol 2003;62:42-5
   PubMed Web of Science ®Google Scholar
• Stratz T, Kees F, Muller W. Do cytochrome enzymes influence the therapeutic effect of fibromyalgia? Drugs Exp Clin Res 2003;29:91-4
   PubMedGoogle Scholar
• Muller W, Stratz T. Results of the intravenous administration of tropisetron in fibromyalgia patients. Scand J Rheumatol 2000;29(Suppl 113):59-62
   Google Scholar
• Spath M, Stratz T, Neeck G, Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 2004;33:267-70
   PubMed Web of Science ®Google Scholar
• Tolk J, Kohnen R, Muller W. Intravenous treatment of fibromyalgia with 5HT3 receptor antagonist tropisetron in a rheumatological practice. Scand J Rheumatol 2004;33(Suppl 119):72-5
   Google Scholar
• Wolf H. Preclinical and clinical pharmacology of 5HT3 receptor antagonists. J Scand Rheumatol 2000;29(Suppl 113):37-45
   Google Scholar
• Haus U, Spath M, Farber L. Spectrum of use and tolerability of 5HT3 receptor antagonists. Scand J Rheumatol 2004;333(Suppl 119):12-18
   Google Scholar
• Stratz T, Muller W. The effect of the 5HT3 receptor antagonist tropisetron on pain caused by secondary fibromyalgia. Fortschr Med 2002;120:17-20
   Google Scholar
• Stratz T, Muller W. Treatment of systemic sclerosis with the 5HT3 receptor antagonist tropisetron. Scand J Rheumatol 2004;33(Suppl 119):59-62
   PubMedGoogle Scholar
• Salemi S, Rethage J, Wollina U, Detection of interleukin 1-beta, interleukin 6 and tumor necrosis factor alpha in skin of patients with fibromyalgia. J Rheumatol 2003;30:148-50
   Web of Science ®Google Scholar
• Mulington JM, Hinze-Selch D, Pollmacher T. Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions. Ann NY Acad Sci 2001;933:201
   PubMed Web of Science ®Google Scholar
• Gur A, Karakoc M, Erdogan S, Regional cerebral blood flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol 2002;20:753-60
   PubMedGoogle Scholar
• Wallace DJ, Linker-Israeli M, Hallegua D, Cytokines play an aetiopathogenetic role in fibromyalgia. A hypothesis and pilot study. Rheumatology 2001;40:743-9
   PubMed Web of Science ®Google Scholar
• Muller W, Schneider M, Joos T, A model for subgrouping fibromyalgia syndrome. Schmerz 2007;21(5):424-9
   PubMedGoogle Scholar
• Oen K, Robinson DR, Nickerson P, Familial seropositive rheumatoid arthritis in north American native families: effects of shared epitope and cytokine genotypes. J Rheumatol 2005;32:983-91
   PubMedGoogle Scholar
• Burckhardt CS, O'Reilly CA, Wiens NA, Assessing depression in fibromyalgia patients. Arthritis Care Res 1994;7:35-9
   PubMedGoogle Scholar
• Fassbender K, Samborski W, Kellner M, Tender points, depressive and functional symptoms. Comparison between fibromyalgia and major depression. Clin Rheumatol 1997;16:76-9
   PubMed Web of Science ®Google Scholar
• Hudson JL, Pope HG Jr. The relationship between fibromyalgia and major depressive disorder. Dis Clin North Am 1996;22:285-303
   Web of Science ®Google Scholar
• Anderberg UM, Martendottir I, von Knorring L. Citalopram in patients with fibromyalgia – a randomized, double-blind, placebo-controlled study. Eur J Pain 2000;4:27-35
   PubMed Web of Science ®Google Scholar
• Arnold LM, Rosen A, Pritchett YL, A randomized double-blind placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with and without major depression. Pain 2005;119:5-15
   PubMed Web of Science ®Google Scholar
• Gendreau RM, Thorn MD, Gendreau JF, Efficacy of minacipram in patients with fibromyalgia. J Rheumatol 2005;32:1975-85
   PubMed Web of Science ®Google Scholar
• O'Malley PG, Balden E, Tomkins G, Treatment of fibromyalgia with antidepressants: a metaanalysis. J Gen Intern Med 2000;15:659-66
   PubMed Web of Science ®Google Scholar
• Thomas E, Blotmann F. Are antidepressants effective in fibromyalgia? Joint Bone Spine 2001;69:531-3
   Web of Science ®Google Scholar
• Uceyler N, Hauser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum 2008;59(9):1279-98
   PubMedGoogle Scholar
• Hauser W, Bernardy K, Uceyler N, Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009;301(2):198-209
   PubMed Web of Science ®Google Scholar
• Hauser W, Eich W, Herrmann M, Fibromyalgia syndrome – Classification, diagnosis and treatment. Dtsch Aerztebl Int 2009;106:383-92
   PubMed Web of Science ®Google Scholar
• Goldenberg DL. Update on the treatment of fibromyalgia. Bull Rheum Dis 2004;53:1-7
   Google Scholar
• Ginsberg F, Mancaux A, Joos E, A randomized placebo-controlled trial of substained-release amitriptylin in primary fibromyalgia. J Musculoskelet Pain 1996;4:37-47
   Google Scholar
• Lucchelli A, Santagostino-Barbone MG, Candura SM, Tonini M. The interaction of antidepressant drugs with central and peripheral (enteric) 5HT3 and 5HT4 receptors. Br J Pharmacol 1995;114:1017-25
   PubMed Web of Science ®Google Scholar
• Wolfe F, Cathey MA, Hawley DJ. A double blind placebo-controlled trial of fluoxetin in fibromyalgia. Scand J Rheumatol 1994;23:255-9
   PubMed Web of Science ®Google Scholar
• Arnold LM, Hess EA, Hudson JI, A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetin in treatment of women with fibromyalgia. Am J Med 2002;112:191-7
   PubMed Web of Science ®Google Scholar
• Patkar AA, Masand PS, Krulewicz S, randomized, controlled, trial of release paroxetin in fibromyalgia. Am J Med 2007;120:448-54
   PubMed Web of Science ®Google Scholar
• Goldenberg D, Mayskiy M, Mossey C, A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-9
   PubMed Web of Science ®Google Scholar
• Uceyler N, Offenbacher M, Petzke F, New treatment options for fibromyalgia: critical appraisal of duloxetine. Neuro Psychiatr Dis Treat 2008;4:525-9
   PubMedGoogle Scholar
• Scholz BA, Hammonds CL, Boomeshine CS. Duloxetine for the management of fibromyalgia syndrome. J Pain Res 2009;2:99-108
   PubMedGoogle Scholar
• Clauw DJ, Mease P, Palmer RH, Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004
   PubMed Web of Science ®Google Scholar
• Nagaoka S, Ohno M, Sekiguchi A. An open-label clinical trial of milacipran in fibromyalgia syndrome with comorbid depressive symptoms. Int J Psychiatr Clin Pract 2004;8:7-51
   Web of Science ®Google Scholar
• Lyseng-Williamson KKA, Siddiqui M, Asif A. Pregabalin: a review of its use in fibromyalgia. Drugs 2008;68:2205-23
   PubMed Web of Science ®Google Scholar
• Arnold LM, Russel RW, Florian H, Pregabalin monotherapy for relief of symptoms of fibromyalgia syndrome: analysis of two double-blind, randomized, placebo-controlled trials. Ann Rheum Dis 2007;66(Suppl II):62
   Google Scholar
• Crofford LJ, Rowbotham MC, Mease PJ, Pregabalin 1008-105 study group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo controlled trial. Arthritis Rheum 2005;52:1264-73
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Simpson SI, Young JP, The fibromyalgia relapse evaluation and efficacy for durability of meaningful relief trial, a 6-month, double blind, placebo-controlled trial of pregabalin as treatment of fibromyalgia syndrome. Ann Rheum Dis 2007;66(Suppl II):61
   Google Scholar
• Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprin. A meta-analysis. Arthritis Rheum 2004;51:9-13
   PubMed Web of Science ®Google Scholar
• Childers MK, Borenstein D, Brown RL, Low-dose cyclobenzaprine versus combination therapy with ibuprofen for acute neck or back pain with muscle spasm: a randomized trial. Curr Med Res Opin 2005;21:1485-93
   PubMed Web of Science ®Google Scholar
• Vaeroy H, Abrahamsen A, Forre O, Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp) versus placebo. Clin Rheumatol 1989;8:245-50
   PubMed Web of Science ®Google Scholar
• Bennet RM, Schein J, Kosinski MR, Impact of fibromyalgia pain on health-relatet quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum 2005;53:519-25
   PubMedGoogle Scholar
• Muller W, Stratz T. Using 5HT3 receptor antagonists in fibromyalgia patients treated with morphine. Akt Rheumatol 2003;28:266-8
   Web of Science ®Google Scholar
• Bennet RM, Clark SC, Walczyk J. A randomized double-blind, placebo controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998;104:227-31
   PubMed Web of Science ®Google Scholar
• Sorensen J, Bengtsson A, Backman E, Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocain and ketamine. Scand J Rheumatol 1995;24:360-5
   PubMed Web of Science ®Google Scholar
• Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist in patients with fibromyalgia receiving concomitant medication. Arthritis Rheum 2005;52:2495-505
   PubMed Web of Science ®Google Scholar
• Raphael JH, Southall JL, Treharne GJ, Kitas GD. Efficacy and adverse effects of intravenous lidocain therapy. BMC Musculoskelet Disord 2002;3:1-8
   PubMed Web of Science ®Google Scholar
• Hannonen P, Malminiemi K, Yli-Kerttula U, A randomized, double-blind, placebo-controlled study of moclobenide and amitriptyline in the treatment of fibromyalgia in female without psychiatric disorder. Br J Rheumatol 1998;37:1279-86
   PubMedGoogle Scholar
• Scharf MB, Baumann M, Berkowitz DV. Effects of sodium oxybate on sleep physiology and sleep/wake-related symptoms in patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. J Rheumatol 2010;37(10):2156-66
   PubMed Web of Science ®Google Scholar
• Staud R. Pharmacological treatment of fibromyalgia syndrome: new developments. Drugs 2010;70:1-14
   PubMed Web of Science ®Google Scholar
• Egle UT. Somatoform disorders – an update. MMW Fortschr Med 2005;147:6-14
   Google Scholar
• Thieme K, Cromnica-Ihle E, Flor H. Operant behavioral treatment of fibromyalgia: a controlled study. Arthritis Rheum 2003;49:314-20
   PubMed Web of Science ®Google Scholar
• Montoya R, Sitges C, Carda-Herrera M, Abnormal affective modulation of somatosensory brain processing among patients with fibromyalgia. Psychosom Med 2005;57:957-63
   Google Scholar
• May A. Review: chronic pain may change the structure of the brain. Pain 2008;137:7-15
   PubMed Web of Science ®Google Scholar
• Simons DG, Travell J. Myofascial pain dysfunction. The trigger point manual. 2nd edition. Williams and Williams, Baltimore; 1999
   Google Scholar
• Bruckle W, Suckfull M, Fleckenstein W, Tissue pO2 measurement in taut back musculature (M. erector spinae). Z Rheumatol 1999;49:208-16
   Google Scholar
• Shah JP, Phillips T, Danoff JV, Gerber L. A novel microanalytical technique for assaying soft tissue demonstrates significant quantitative biochemical differences in 3 clinically distinct groups: normal, latent and active. Arch Phys Med Rehabil 2003;84: abstract 17
   Google Scholar
• Hong CZ, Hsuch TC. Difference in pain relief after trigger point injection in myofascial pain patients with and without fibromyalgia. Arch Phys Med Rehabil 1996;77:1161-6
   PubMed Web of Science ®Google Scholar
• Muller W, Stratz T. Local treatment of tendinopathies and myofascial pain syndrome with the 5HT3 receptor antagonist tropisetron. Scand J Rheumatol 2004;33(Suppl 119):44-8
   PubMedGoogle Scholar
• Muller W, Kelemen J, Stratz T. Spinal factors in the generation of fibromyalgia. Rheumatol 1998;57(Suppl 2):36-42
   Google Scholar
• Lapossy E, Maleitzke R, Hrycaj P, The frequency of transition of chronic low back pain to fibromyalgia. Scand J Rheumatol 1995;24:29-33
   PubMed Web of Science ®Google Scholar
• Samborski W, Stratz T, Kretzmann WM, Analysis on occurrence of vegetative and functional complains in low back pain in comparison with fibromyalgia. Z Rheumatol 1991;50:21-2
   PubMed Web of Science ®Google Scholar